The DIA 2023 Global Annual Meeting invites industry, regulatory government, academics, and patients to network, problem solve, and discuss global and local challenges facing the life sciences community. Hosted in Boston, DIA 2023 will amplify different perspectives while highlighting expertise across the globe to reimagine current processes that better enhance health and well-being. Register Today.
Cell and gene therapies face steeper challenges at launch than traditional drugs do, potentially limiting their adoption and thus their potential to transform patients’ lives. This article examines key considerations for strategic market access and launch excellence.
Explore the potential of ribonucleoprotein (RNP) to deliver CRISPR materials more accurately, efficiently, and effectively, as well as the manufacturing challenges which require further attention.
Article |
By Brian Fidler and Muhammad Siddiqui,Entegris, Inc.
Freezing biologics is a complex undertaking. As more biotherapies enter the market, ensuring manufacturers have the technology to optimize their cold chain applications is paramount.
Article |
By Gregg Johnson and Evan Hagen,Charter Medical
Single-use strategies and tools are constantly evolving to better serve industry needs, and adept solutions providers can help streamline development with simple, custom adaptations.
Read more about what a facility needs to achieve operational readiness and the necessary steps to take to be at full scale production when the “go” button is hit.
LVVs are emerging as an indispensable tool for gene therapy, but they present significant complications for purification and concentration. Technological advancements and method optimization can help developers navigate these hurdles.
Experts discuss several ways in which natural killer (NK) cells can offer a path forward as a deliver platform for engineered cell (and ex vivo gene) therapy. Explore four different aspects of cytotoxic cell therapy.
Application Note |
Applied Biosystems by Thermo Fisher Scientific, qPCR
What are viral-based vectors and why are reproducible quantitation of gene expression important in gene therapy? Explore these questions through a demonstration of well-to-well and instrument-to-instrument data concordance across biosystems.
Examine the first commercial live shipment of temperature-critical autologous final CAR-T drug product from a U.S. manufacturing site to a hospital in Japan.
Therapies based on messenger RNA, such as mRNA vaccines, have revolutionary potential. Learn more about key objectives, considerations, and strategies in mRNA manufacturing.
While biotech companies face pressure to rush to trials, development still requires a significant amount of work. This panel explores the pitfalls for developers and indicators of GMP readiness.
